“We have developed a CPD-approved learning module on benzodiazepines for clinical practitioners. The self-directed learning package outlines the key risks of this widely prescribed class of medicines. The learning module outlines:

 

  • the main features of the adverse effect
  • factors that increase the risk
  • how the risk can be reduced
  • specific treatment for the adverse effect

Used with authoritative medicines information and guidelines on disease management, this module is an important and practical aid to doctors, pharmacists and nurses caring for individuals who might need treatment with a benzodiazepine. Self-assessment questions, together with full feedback, accompany the learning material. Surveys tell us that learners greatly value the questions and the detailed feedback in our modules. This module incorporates a dozen self-assessment questions around important risks and their management.

 

Participants are invited to complete a short online evaluation form at the end of the module—responses enable us to tailor our modules to users’ needs. The learning module on benzodiazepines has been approved for up to 2.5 CPD credits by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.

 

This benzodiazepine learning module joins similar CPD-approved MHRA modules on selective serotonin reuptake inhibitors, opioids, and antipsychotics. You can access the full range of MHRA learning modules on devices and medicines through the Education page of our website.”

Posted on the UK MHRA website on 12 March 2013